Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Exelixis
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT05445609CT.gov Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | — | Suspended | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05150236CT.gov EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | — | Unknown | — | — | — |
NCT04989946CT.gov Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT05655715CT.gov Checkpoint Inhibitors and SBRT for MCRPC | — | Completed | — | — | — |
NCT04159896CT.gov ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
NCT03879122CT.gov A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | — | Unknown | — | — | — |
Show 15 more trialsShow fewer
NCT03815942CT.gov VAccination in Early and ADvanced Prostate caNCEr | — | Terminated | — | — | — |
NCT03651271CT.gov Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | — | Completed | — | — | — |
NCT03689699CT.gov Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | — | Active Not Recruiting | — | — | — |
NCT03532217CT.gov Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT03600350CT.gov pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03554317CT.gov COMbination of Bipolar Androgen Therapy and Nivolumab | — | Completed | — | — | — |
NCT03572478CT.gov Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | — | Terminated | — | — | — |
NCT03061539CT.gov Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | — | Active Not Recruiting | — | — | — |
NCT03333616CT.gov Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT03338790CT.gov An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT02933255CT.gov PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | — | Completed | — | — | — |
NCT02985957CT.gov A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | — | Completed | — | — | — |
NCT02601014CT.gov Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00441337CT.gov A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Exelixis | P3 | B · 59 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →